Navigation Links
SemBioSys Genetics Inc. Announces Clinical Results with Plant-Produced Insulin
Date:3/19/2009

plant seeds to USP and EP standards and finally, we have obtained regulatory approval in the US and Europe to administer SBS 1000 in a phase I/II clinical trial, where our insulin was been found to be biologically active without any unexpected adverse reactions," commented James Szarko, Chief Executive Officer at SemBioSys. "We are continuing optimization work targeted at streamlining the production process to further improve cost of goods."

About SemBioSys

Calgary, Alberta-based SemBioSys is a world leader in manufacturing high-value proteins and oils in plant seeds. With its unique, proprietary platform, SemBioSys provides partners with product enablement, exceptionally low cost and unprecedented scalability. The Company applies this platform with high selectivity to opportunities where it has a unique competitive advantage. Since its inception, SemBioSys has produced more than 50 non-native proteins and oils using its patented seed technology, demonstrating applicability across a broad range of industries such as pharmaceuticals, personal care and industrial products. The Company's current pharmaceutical development programs include insulin (SBS-1000, regulated as a biosimilar in Europe) and Apo AI(Milano), a next-generation cardiovascular therapy. SemBioSys is listed on the Toronto Stock Exchange under the ticker SBS. More information is available at www.sembiosys.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could ca
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. SemBioSys announces senior management changes
2. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
3. SemBioSys begins phase I/II trial of insulin produced in plant seeds
4. SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND
5. SemBioSys announces second quarter 2008 financial and operational results
6. SemBioSys submits IND for safflower-produced insulin to U.S. FDA
7. SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
8. SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference
9. SemBioSys provides update on shrimp feed additive, Immunosphere(TM)
10. SemBioSys announces first quarter 2008 financial and operational results
11. SemBioSys receives milestone payments from AVAC Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014  Sigma-Aldrich Corporation (NASDAQ: SIAL ) ... its investment in Green Chemistry and donated more than ... year, the Company announced Monday in its new ... World? The report comes in a ... a responsible corporate citizen, including recognition for the second ...
(Date:7/29/2014)...  United Therapeutics Corporation (NASDAQ: ... for the second quarter ended June 30, 2014. ... our medicines are reaching increasing numbers of ... said Martine Rothblatt, Ph.D., United Therapeutics, Chairman ... this quarter of our extended-release tablet called ...
(Date:7/29/2014)... San Diego, CA (PRWEB) July 29, 2014 ... added to Pipette.com’s centrifugation product selection. Eppendorf 5427 R ... reverse engineering, and DNA – it is targeted towards ... the Eppendorf Centrifuge 5427 R as it compliments their ... as their Eppendorf line of microcentrifuge tubes, PCR tubes, ...
(Date:7/29/2014)... 29, 2014 White papers by ... cloud based eClinical technologies, have been published by leading ... follow a long line of white papers by Clinovo ... Life Science Leader, Pharmaceutical Online, and OpenHealthNews. , At ... paper by CTO Marc Desgrousilliers, 'The Five Essentials ...
Breaking Biology Technology:Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13International Pipette Distributor, Pipette.com Announces the Addition of the Eppendorf Centrifuge 5427 R to Their Product Portfolio 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 3
... Hefty has seen blue-ribbon government panels come and go ... thick file of reports spanning 20 years of commissions, ... thoughtful research papers is only useful if it leads ... Hefty, who retired last year from Blue-Cross/Blue Shield United ...
... Role in Community...promotes entertainment everywhere on any device ... approval for the sale of the companys desktop products ... (SPD) The transaction is now complete and Sony Pictures ... it will keep the companys employee base in Madison ...
... alternative energy , ,Madison, WI - WE Energies ... two developers that will build three wind farms increasing ... by 400%. , ,Under the agreement, the two developers, ... LLC, based in Chicago, will provide their entire energy ...
Cached Biology Technology:Governors Growth Council hopes to go light on paperwork and heavy on ideas 2Governors Growth Council hopes to go light on paperwork and heavy on ideas 3Sony Completes Acquisition of Sonic Foundry 2Sony Completes Acquisition of Sonic Foundry 3WE Energies Is Not Letting Wind Power Blow Away 2
(Date:7/29/2014)... UC San Francisco is the first to show that ... accelerate cellular aging, these negative effects may be reduced ... , "The study participants who exercised, slept well ... ones who didn,t maintain healthy lifestyles, even when they ... Puterman, PhD, assistant professor in the department of psychiatry ...
(Date:7/28/2014)... U.S. Food and Drug Administration (FDA) for other purposes ... inside human cells, including those that cause Legionnaires, disease, ... mBio , the online open-access journal of the ... identifying non-antibiotic drugs that could one day help curb ... the list inhibit the growth of at least three ...
(Date:7/28/2014)... signs of damage from the Deepwater Horizon oil spill expands ... of Mexico. The discovery was made by a team led ... A paper describing this work and additional impacts of human ... published during the last week of July 2014 in the ... National Academy of Sciences . , "The footprint of the ...
Breaking Biology News(10 mins):Healthy lifestyle may buffer against stress-related cell aging, study says 2New route to identify drugs that can fight bacterial infections 2Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2
... comparing the immune responses of both, young and old ... of macrophages, one of the major cell populations involved ... aged mice. This decline in the number of fighters ... be responsible for the age-associated increase in susceptibility to ...
... 2010 Burnham Institute for Medical Research (Burnham) announced ... million to support and further expand and accelerate the ... been renamed the Sanford-Burnham Medical Research Institute. This is ... 2007, he directed $20 million through Sanford Health to ...
... FAIRFAX, Va.Nearly 5,300 physicians, scientists and allied health ... Interventional Radiology,s 35th Annual Scientific Meeting March 13󈝾 ... are scheduled for 9󈝶:30 a.m. on both Monday, ... Annual Scientific Meeting offers ...
Cached Biology News:Rejuvenating the old immune system 2T. Denny Sanford donates $50 million to Burnham Institute for Medical Research 2Press registration open for Society of Interventional Radiology’s 35th Annual Scientific Meeting 2
Rabbit Anti-Ferret Whole Serum Antibody, Unconjugated...
... microPET R4 is the lowest priced, ... in the world. Despite the microPET ... competing systems in all performance categories; count ... feature set., microPET is a dedicated small ...
... product has been developed to significantly increase ... proteins. Stability is increased at room ... centigrade. This product is subjected to ... or azide. This formulation insures consistently ...
... utilizies CTI Molecular Imaging's proprietary Focus™ ... sensitivty, and a large imaging volume ... to image multiple mice or large ... a dedicated small animal PET (Positron ...
Biology Products: